drugset / Trial / NCT02680756

Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

NCT02680756

Phase 3 Completed 250 enrolled Shield Therapeutics
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the efficacy of ferric maltol and intravenous iron (IVI) Ferric Carboxy Maltose in the treatment of iron deficiency anaemia (IDA) and subsequent maintenance of haemoglobin in subjects with Inflammatory Bowel Disease (IBD).

Timeline

Start
2016-01
Primary completion
2018-10
Completion
2019-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ferric carboxymaltose Other / unclassified Intravenous
Subject Ferric maltol Small molecule 30 mg Oral